BioWorld's latest installment in its series on brain–computer interfaces reports that Ability Neurotech SA and a new cohort of BCI companies are positioning themselves as fast followers to early entrants such as Neuralink.

Rotem Kopel, CEO of Ability Neurotech SA, told BioWorld: "It's not too bad to be a fast follower to a company like Neuralink." Kopel said her company and peers are using that position to focus on different device designs and indications rather than repeating the same path as the pioneers.

Companies described in the piece are pursuing two broad strategies. One is building more complete system stacks—hardware, software and clinical workflows—so devices can move from lab demonstrations toward sustained clinical use. The other is exploring alternative hardware approaches, from electrodes made with newer materials to particle-based delivery such as nanoparticles.

The article notes firms are explicitly tackling technical and clinical challenges highlighted by earlier entrants. Those challenges include long-term implant reliability, the surgical footprint of devices, and clinical pathways for indications beyond motor restoration. The newer companies say addressing those gaps could broaden which patients and conditions are targetable.

BioWorld frames this as an ecosystem shift rather than a single technological breakthrough. Kopel and the companies cited are focusing on incremental engineering work, regulatory planning and different therapeutic targets as routes to commercial and clinical viability.

Details on specific products, trial sizes or regulatory milestones were not given in the summary. The piece centers on strategy and direction for the next wave of BCI startups rather than new clinical data.

Photo credit: www.bioworld.com

Tags: brain–computer interfaces, BCI hardware, electrode materials, neural implants, Ability Neurotech

Topics: Neurotech industry & startups, Brain–computer interfaces, Neuroprosthetics & neural implants